Regeneron Pharmaceuticals Inc (NASDAQ: REGN) crashed more than 15% this morning on disappointing data from Phase 3 trials of its experimental drug itepekimab.Itepekimab is a drug candidate for chronic obstructive pulmonary disease (COPD) that the biotech firm developed with Paris headquartered Sanofi.Including today’s plummet, REGN shares are down nearly 35%…
Trump administration has reportedly picked Palantir Technologies Inc. (NASDAQ: PLTR) as its primary data analysis partners. Shares of the…
German automaker Volkswagen said the company is planning to increase investments in the US to reduce the impact of…
Intel has announced plans to lower its global headcount by more than 20% under the leadership of Lip-Bu Tan,…
Sunrun Inc (NASDAQ: RUN) has been a major disappointment for investors in recent weeks, but a senior analyst at…
German stocks have been on a tear in 2025, vastly outperforming both their European peers and U.S. counterparts.The DAX…
Gap Inc (NYSE: GAP) shares plunged some 20% on Friday, rattled by concerns over tariffs and their potential impact…
U.S. equities may be poised for a significant rally in the second half of 2025, according to Chris Harvey,…
Bitcoin remains stuck below $110,000 as the financial landscape maintains a cautious tone following the latest Fed updates.While most…